Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GTB-5550
- Development stage
- Phase 1
- Lead developer
- GT Biopharma
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GTB-5550 is a novel tri-specific killer engager (TriKE) recombinant fusion protein developed by GT Biopharma. It is designed to enhance natural killer (NK) cell-mediated cytotoxicity against solid tumors by simultaneously engaging three targets: CD16 on NK cells to activate them; tumor antigens such as PSMA or B7-H3 expressed on cancer cells for targeted binding; and an interleukin 15 (IL-15) moiety to stimulate NK cell proliferation and persistence. The drug aims to overcome the limitations of current immunotherapies in solid tumors by providing antigen-specific targeting and boosting NK cell function within the tumor microenvironment. Its primary indications are for multiple solid tumors including prostate, breast, head and neck, ovarian, lung, and gastrointestinal cancers[1][4][6].
- Brand names
- TriKE
- Other names
- B7H3 TriKEB-7H3 TriKEB 7H3 TriKEcam1615B7H3cam-1615B7H3cam 1615B7H3GTB-5550 TriKEGTB5550 TriKEGTB 5550 TriKE
02
Targets
B7-H3IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)
Beyond the preview
Go deeper on GTB-5550.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GTB-5550.